Arbutus Biopharma Corp (ABUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arbutus Biopharma Corp (ABUS) has a cash flow conversion efficiency ratio of -0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.11 Million) by net assets ($260.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ABUS equity financing ratio to measure how much of total assets are equity-financed.
Arbutus Biopharma Corp - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Arbutus Biopharma Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Arbutus Biopharma Corp (ABUS) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Arbutus Biopharma Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arbutus Biopharma Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hubei Chutian Expressway Co Ltd
SHG:600035
|
0.036x |
|
India Glycols Limited
NSE:INDIAGLYCO
|
0.036x |
|
Hang Xiao Steel Structure Co Ltd
SHG:600477
|
0.025x |
|
Jilin Yatai Group Co Ltd
SHG:600881
|
0.038x |
|
Guilin Seamild Foods Co Ltd
SHE:002956
|
0.078x |
|
Tigerair Taiwan Co. Ltd.
TW:6757
|
0.292x |
|
Ningbo Thermal Power Co Ltd
SHG:600982
|
0.071x |
|
GCI Liberty, Inc.
NASDAQ:GLIBK
|
0.045x |
Annual Cash Flow Conversion Efficiency for Arbutus Biopharma Corp (1998–2025)
The table below shows the annual cash flow conversion efficiency of Arbutus Biopharma Corp from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Arbutus Biopharma Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $76.58 Million | $-39.64 Million | -0.518x | +22.28% |
| 2024-12-31 | $97.37 Million | $-64.85 Million | -0.666x | +17.83% |
| 2023-12-31 | $106.02 Million | $-85.94 Million | -0.811x | -213.75% |
| 2022-12-31 | $136.85 Million | $-35.36 Million | -0.258x | +35.18% |
| 2021-12-31 | $169.44 Million | $-67.53 Million | -0.399x | +21.00% |
| 2020-12-31 | $101.97 Million | $-51.44 Million | -0.504x | +48.32% |
| 2019-12-31 | $72.74 Million | $-71.01 Million | -0.976x | -187.85% |
| 2018-12-31 | $200.23 Million | $-67.90 Million | -0.339x | -27.34% |
| 2017-12-31 | $182.50 Million | $-48.60 Million | -0.266x | +6.61% |
| 2016-12-31 | $203.00 Million | $-57.88 Million | -0.285x | -185.06% |
| 2015-12-31 | $547.68 Million | $-54.78 Million | -0.100x | +29.13% |
| 2014-12-31 | $88.00 Million | $-12.42 Million | -0.141x | -23.99% |
| 2013-12-31 | $59.19 Million | $-6.74 Million | -0.114x | -114.00% |
| 2012-12-31 | $40.92 Million | $33.27 Million | 0.813x | +156.28% |
| 2011-12-31 | $5.21 Million | $-7.52 Million | -1.445x | -37.84% |
| 2010-12-31 | $10.73 Million | $-11.25 Million | -1.048x | -608.93% |
| 2009-12-31 | $35.44 Million | $-5.24 Million | -0.148x | +33.28% |
| 2008-12-31 | $38.29 Million | $-8.48 Million | -0.222x | -49.67% |
| 2007-12-31 | $18.37 Million | $-2.72 Million | -0.148x | +99.12% |
| 2006-12-31 | $155.53K | $-2.62 Million | -16.866x | -2240.30% |
| 2005-12-31 | $-18.49 Million | $-14.57 Million | 0.788x | -17.14% |
| 2004-12-31 | $-10.50 Million | $-9.98 Million | 0.951x | +253.00% |
| 2003-12-31 | $43.38 Million | $-26.96 Million | -0.622x | -55.24% |
| 2002-12-31 | $45.35 Million | $-18.16 Million | -0.400x | -146.08% |
| 2001-12-31 | $61.49 Million | $-10.00 Million | -0.163x | +41.51% |
| 2000-12-31 | $30.03 Million | $-8.35 Million | -0.278x | -9.37% |
| 1999-12-31 | $26.88 Million | $-6.84 Million | -0.254x | +52.39% |
| 1998-12-31 | $14.43 Million | $-7.71 Million | -0.534x | -- |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more